Citations

Mayo Clinic

Showing 10 of 108599 citations.

A US-based national surveillance study for the susceptibility and epidemiology of Clostridioides difficile isolates with special reference to ridinilazole: 2020–2021
Snydman, David R. , McDermott, Laura A. , Thorpe, Cheleste M. , Goldstein, Ellie J. C. , Gerding, Dale N. , Gluck, Linda, Lancaster, Chris, Garey, Kevin W. , Walk, Seth T. , Duperchy, Esther, Snydman, D R , McDermott, L A , Schuetz, Audrey N. , Johnson, Stuart , Bourdas, D., Carroll, Karen C. , Wang, Q.

Antimicrobial Agents and Chemotherapy | September 20, 2023 | Volume: 67 | Issue: 10 | Pages: No page available

10.1128/aac.00349-23 | PMID 37728368 Get It

ABSTRACT We have previously reported on the susceptibility and epidemiology of Clostridioides difficile isolates from six geographically dispersed medical centers in the United States. This current survey was conducted with isolates collected in 2020–2021 from six geographically dispersed medical centers in the United States, with specific attention to susceptibility to ridinilazole as well as nine comparators. C. difficile isolates or stools from patients with C. difficile antibiotic-associated diarrhea were collected and referred to a central laboratory. After species confirmation of 300 isolates at the central laboratory, antibiotic susceptibilities were determined by the agar dilution method [M11-A9, Clinical and Laboratory Standards Institute (CLSI)] against the 10 agents. Ribotyping was performed by PCR capillary gel electrophoresis on all isolates. Ridinilazole had a minimum inhibitory concentration (MIC) 90 of 0.25 mcg/mL, and no isolate had an MIC greater than 0.5 mcg/mL. In comparison, fidaxomicin had an MIC 90 of 0.5 mcg/mL. The vancomycin MIC 90 was 2 mcg/mL with a 0.7% resistance rate [both CLSI and European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria]. The metronidazole MIC 90 was 1 mcg/mL, with none resistant by CLSI criteria, and a 0.3% resistance rate by EUCAST criteria. Among the 50 different ribotypes isolated in the survey, the most common ribotype was 014–020 (14.0%) followed by 106 (10.3%), 027 (10%), 002 (8%), and 078–126 (4.3%). Ridinilazole maintained activity against all ribotypes and all strains resistant to any other agent tested. Ridinilazole showed excellent in vitro activity against C. difficile isolates collected between 2020 and 2021 in the United States, independent of ribotype.
P32 Statistical colocalization identifies twenty-four novel risk loci associated with disease risk of primary biliary cholangitis
Mulcahy, Victoria , Juran, Brian D., Sandford, Richard , Amos, Chris, Seldin, Michael F., Siminovitch, Katherine, Mells, George , Cordell, Heather J. , Atkinson, Elizabeth, Carbone, Marco , Asselta, Rosanna , Andrade, Mariza de , Jones, David, Lazaridis, Konstantinos , Hirschfield, Gideon M. , Invernizzi, Pietro , Wallace, Chris

Poster presentations | September 20, 2023 | Volume: No volume available | Issue: No issue available | Pages: A32.2-A33

10.1136/gutjnl-2023-basl.48 Get It

Tumor-Infiltrating Normal B Cells Revealed by Immunoglobulin Repertoire Clonotype Analysis Are Highly Prognostic and Crucial for Antitumor Immune Responses in DLBCL
Xu‐Monette, Zijun Y. , Li, Yong , Snyder, Thomas M. , Yu, Tiantian , Lu, Tingxun , Tzankov, Alexandar , Visco, Carlo , Bhagat, Govind , Qian, Wenbin , Dybkær, Karen , Chiu, April , Tam, Wayne , Zu, Youli , Hagemeister, Fredrick B., Wang, Yingjun , Ferreri, Andrés J.M. , Møller, Michael , Parsons, Benjamin M. , Fan, Xiangshan , Au, Qingyan , Zhang, Mingzhi , Shaughnessy, John D. , Xu, Bing , Young, Ken H. , Snyder, Thomas , Lu, Tingxun , Hsi, Eric D , Hagemeister, Fredrick B , Wang, Yingjun , Go, Heounjeong , Ponzoni, Maurilio , Ferreri, Andrés J M , Møller, Michael Boe , Parsons, Benjamin M , Fan, Xiangshan , van Krieken, J Han , Piris, Miguel , Winter, Jane N , Au, Qingyan , Kirsch, Ilan , Zhang, Mingzhi , Shaughnessy, John , Xu, Bing , Young, Ken H , Tzankov, Alexandar , Dybkaer, Karen , Li, Yong , Bhagat, Govind , Zu, Youli , Xu-Monette, Zijun Y , Hsi, Eric D. , Go, Heounjeong , Ponzoni, Maurilio , Krieken, J. Han van , Piris, Miguel Á. , Winter, Jane N. , Kirsch, Ilan R.

Clinical Cancer Research | September 20, 2023 | Volume: 29 | Issue: 23 | Pages: 4808-4821

10.1158/1078-0432.ccr-23-1554 | PMID 37728879 Get It

Abstract Purpose: Tumor-infiltrating B lymphocytes (TIL-B) have demonstrated prognostic and predictive significance in solid cancers. In this study, we aimed to distinguish TIL-Bs from malignant B-cells in diffuse large B-cell lymphoma (DLBCL) and determine the clinical and biological significance. Experimental Design: A total of 269 patients with de novo DLBCL from the International DLBCL R-CHOP Consortium Program were studied. Ultra-deep sequencing of the immunoglobulin genes was performed to determine B-cell clonotypes. The frequencies and numbers of TIL-B clonotypes in individual repertoires were correlated with patient survival, gene expression profiling (GEP) data, and frequencies of DLBCL-infiltrating immune cells quantified by fluorescent multiplex IHC at single-cell resolution. Results: TIL-B abundance, evaluated by frequencies of normal B-cell clonotypes in the immunoglobulin repertoires, remarkably showed positive associations with significantly better survival of patients in our sequenced cohorts. DLBCLs with high versus low TIL-B abundance displayed distinct GEP signatures, increased pre-memory B-cell state and naïve CD4 T-cell state fractions, and higher CD4+ T-cell infiltration. TIL-B frequency, as a new biomarker in DLBCL, outperformed the germinal center (GC) B-cell–like/activated B-cell–like classification and TIL-T frequency. The identified TIL-B–high GEP signature, including genes upregulated during T-dependent B-cell activation and those highly expressed in normal GC B cells and T cells, showed significant favorable prognostic effects in several external validation cohorts. Conclusions: TIL-B frequency is a significant prognostic factor in DLBCL and plays a crucial role in antitumor immune responses. This study provides novel insights into the prognostic determinants in DLBCL and TIL-B functions with important therapeutic implications.
Methylated DNA Markers for Sporadic Colorectal and Endometrial Cancer Are Strongly Associated with Lynch Syndrome Cancers
Bramblet, Rachel M. , Bakkum‐Gamez, Jamie N. , Foote, Patrick H. , Taylor, William R. , Berger, Calise K. , Gysbers, Brianna J. , Arndt, Jacquelyn , Chen, Longwen , Doering, Karen A. , Burger, Kelli N. , Samadder, N. Jewel , Slettedahl, Seth W , Foote, Patrick H , Taylor, William R , Berger, Calise K , Gysbers, Brianna J , Arndt, Jacquelyn , Chen, Longwen , Doering, Karen A , Burger, Kelli N , Mahoney, Douglas W , Sherman, Mark E , Kisiel, John B , Samadder, N Jewel , Slettedahl, Seth W. , Mahoney, Douglas W. , Sherman, Mark E. , Kisiel, John B.

Cancer Prevention Research | September 20, 2023 | Volume: 16 | Issue: 11 | Pages: 611-620

10.1158/1940-6207.capr-23-0107 | PMID 37728516 Get It

Abstract Lynch syndrome (LS) markedly increases risks of colorectal and endometrial cancers. Early detection biomarkers for LS cancers could reduce the needs for invasive screening and surgical prophylaxis. To validate a panel of methylated DNA markers (MDM) previously identified in sporadic colorectal cancer and endometrial cancer for discrimination of these cancers in LS. In a case–control design, previously identified MDMs for the detection of colorectal cancer and endometrial cancer were assayed by qMSP on tissue-extracted DNA. Results were normalized to ACTB values within each sample. Least absolute shrinkage and selection operator models to classify colorectal cancer and endometrial cancer were trained on sporadic cases and controls and then applied to classify colorectal cancer and endometrial cancer, in those with LS, and cross-validated. We identified colorectal cancer cases (23 with LS, 48 sporadic), colorectal controls (32 LS, 48 sporadic), endometrial cancer cases (30 LS, 48 sporadic), and endometrial controls (29 LS, 37 sporadic). A 3-MDM panel (LASS4, LRRC4, and PPP2R5C) classified LS-CRC from LS controls with an AUC of 0.92 (0.84–0.99); results were similar for sporadic colorectal cancer. A 6-MDM panel (SFMBT2, MPZ, CYTH2, DIDO1, chr10.4479, and EMX2OS) discriminated LS-EC from LS controls with an AUC of 0.92 (0.83–1.0); the AUC for sporadic endometrial cancer versus sporadic controls was nominally higher, 0.99 (0.96–1.0). MDMs previously identified in sporadic endometrial cancer and colorectal cancer discriminate between endometrial cancer and benign endometrium and colorectal cancer and benign colorectum in LS. This supports the inclusion of patients with LS within future prospective clinical trials evaluating endometrial cancer and colorectal cancer MDMs and may provide a new avenue for cancer screening or surveillance in this high-risk population. Prevention Relevance: Lynch syndrome (LS) markedly increases risks of colorectal and endometrial cancers. Early detection biomarkers for LS cancers could reduce the needs for invasive screening and surgery. Methylated DNA markers previously identified in sporadic endometrial cancer and colorectal cancer discriminate between benign and cancer tissue in LS.
The Inherited KRAS -variant as a Biomarker of Cetuximab Response in NSCLC
Weidhaas, Joanne B. , Hu, Chen , Komaki, Ritsuko , Masters, Gregory A. , Blumenschein, George R. , Chang, Joe Y. , Lu, Bo , Dicker, Adam P. , Bogart, Jeffrey A. , Garces, Yolanda I. , Narayan, Samir , Robinson, Clifford G. , Kavadi, Vivek S. , Koprowski, Christopher D. , Welsh, James W. , Gore, Elizabeth , MacRae, Robert M. , Bradley, Jeffrey D. , Greenberger, Joel S , Koprowski, Christopher D , Welsh, James , MacRae, Robert M , Paulus, Rebecca , Bradley, Jeffrey , Robinson, Clifford , Dicker, Adam P , Paulus, Rebecca

Cancer Research Communications | September 20, 2023 | Volume: 3 | Issue: 10 | Pages: 2074-2081

10.1158/2767-9764.crc-23-0084 | PMID 37728512 Get It

Abstract Purpose: RTOG 0617 was a phase III randomized trial for patients with unresectable stage IIIA/IIIB non–small cell lung cancer comparing standard-dose (60 Gy) versus high-dose (74 Gy) radiotherapy and chemotherapy, plus or minus cetuximab. Although the study was negative, based on prior evidence that patients with the KRAS-variant, an inherited germline mutation, benefit from cetuximab, we evaluated KRAS-variant patients in RTOG 0617. Experimental Design: From RTOG 0617, 328 of 496 (66%) of patients were included in this analysis. For time-to-event outcomes, stratified log-rank tests and multivariable Cox regression models were used. For binary outcomes, Cochran—Mantel–Haenzel tests and multivariable logistic regression models were used. All statistical tests were two sided, and a P value <0.05 was considered significant. Results: A total of 17.1% (56/328) of patients had the KRAS-variant, and overall survival rates were similar between KRAS-variant and non-variant patients. However, there was a time-dependent effect of cetuximab seen only in KRAS-variant patients—while the hazard of death was higher in cetuximab-treated patients within year 1 [HR = 3.37, 95% confidence interval (CI): 1.13–10.10, P = 0.030], death was lower from year 1 to 4 (HR = 0.33, 95% CI: 0.11–0.97, P = 0.043). In contrast, in non-variant patients, the addition of cetuximab significantly increased local failure (HR = 1.59, 95% CI: 1.11–2.28, P = 0.012). Conclusions/Discussion: Although an overall survival advantage was not achieved in KRAS-variant patients, there is potential impact of cetuximab for this genetic subset of patients. In contrast, cetuximab seems to harm non-variant patients. These findings further support the importance of genetic patient selection in trials studying the addition of systemic agents to radiotherapy. Significance: The KRAS-variant is the first functional, inherited miRNA-disrupting variant identified in cancer. Our findings support that cetuximab has a potentially beneficial impact on KRAS-variant patients treated with radiation. The work confirms prior evidence that KRAS-variant patients are a subgroup who are especially sensitive to radiation. These findings further support the potential of this class of variants to enable true treatment personalization, considering the equally important endpoints of response and toxicity.
Relationship between the rate of fluid resuscitation and acute kidney injury: A retrospective cohort study
Reddy, Swetha , Hu, Bo , Kashani, Kianoush

International Journal of Critical Illness and Injury Science | September 20, 2023 | Volume: 13 | Issue: 3 | Pages: 104-110

10.4103/ijciis.ijciis_7_23 | PMID 38023572 Get It

ABSTRACT Background: Septic shock is the leading cause of acute kidney injury (AKI) in critically ill patients. The foundation of early septic shock management includes early fluid resuscitation, but the association between fluid resuscitation rates and kidney outcomes remains unclear. This investigation examines the association between fluid resuscitation rate and AKI recovery. Methods: In the medical intensive care unit of Mayo Clinic Rochester, adult patients with AKI and septic shock were retrospectively studied from January 1, 2006 to May 31, 2018. The surviving sepsis campaign recommends an initial fluid bolus of 30 ml/kg for sepsis resuscitation. The cohort of patients was divided into three groups based on the average fluid resuscitation time (<1 h, 1.1–3 h, >3 h) and the corresponding fluid rate ≥0.5, 0.17–0.49, and <0.17 ml/kg/min, respectively. The primary outcome was the recovery of AKI on day 7. To account for potential confounders, multivariable regression analyses were conducted. Results: After meeting the eligibility, 597 patients were included in the analysis. The AKI recovery was considerably different among the groups ( P = 0.006). Patients in group 1 who received fluid resuscitation faster had a higher rate of AKI recovery (53%) compared to group 2 and group 3 (50% and 37.8%). Conclusion: In septic shock patients with AKI, a higher fluid resuscitation rate of 30 ml/kg IV fluids within the 1 st -h sepsis diagnosis (i.e., >0.50 ml/kg/min) lead to higher AKI recovery compared with slower infusion rates.
Addressing the Risks of Respiratory Syncytial Virus for Patients With Inflammatory Bowel Disease in the Era of Novel Vaccines
Smith, Ryan A. , Desai, Aakash , Farraye, Francis A. , Caldera, Freddy , Caldera, Freddy , Farraye, Francis A , Desai, Aakash , Hashash, Jana G. , Hayney, Mary S.

Inflammatory Bowel Diseases | September 20, 2023 | Volume: 29 | Issue: 11 | Pages: 1842-1845

10.1093/ibd/izad233 | PMID 37816231 Get It

Intrinsic resistance to ROS1 inhibition in a patient with CD74‐ROS1 mediated by AXL overexpression
Peters, Tara L., Chen, Nan , Le, Anh T. , Doebele, Robert C. , Tyler, Logan C. , Dimou, Anastasios

Thoracic Cancer | September 20, 2023 | Volume: 14 | Issue: 33 | Pages: 3259-3265

10.1111/1759-7714.15116 | PMID 37727007 Get It

AbstractBackgroundThe vast majority of patients with ROS1 positive non‐small cell lung cancer (NSCLC) derive clinical benefit from currently approved ROS1 therapies, including crizotinib and entrectinib. However, a small proportion of patients treated with ROS1 inhibitors fail to derive any clinical benefit and demonstrate rapid disease progression. The biological mechanisms underpinning intrinsic resistance remain poorly understood for oncogene‐driven cancers.MethodsWe generated a patient‐derived cell line, CUTO33, from a ROS1 therapy naive patient with CD74‐ROS1+ NSCLC, who ultimately did not respond to a ROS1 inhibitor. We evaluated a panel of ROS1+ patient‐derived NSCLC cell lines and used cell‐based assays to determine the mechanism of intrinsic resistance to ROS1 therapy.ResultsThe CUTO33 cell line expressed the CD74‐ROS1 gene fusion at the RNA and protein level. The ROS1 fusion protein was phosphorylated at baseline consistent with the known intrinsic activity of this oncogene. ROS1 phosphorylation could be inhibited using a wide array of ROS1 inhibitors, however these inhibitors did not block cell proliferation, confirming intrinsic resistance in this model and consistent with the patient's lack of response to a ROS1 inhibitor. CUTO33 expressed high levels of AXL, which has been associated with drug resistance. Combination of an AXL inhibitor or AXL knockdown with a ROS1 inhibitor partially reversed resistance.ConclusionsIn summary, we demonstrate that AXL overexpression is a mechanism of intrinsic resistance to ROS1 inhibitors.
Pathogenesis‐directed treatment of linear porokeratosis with topical cholesterol‐lovastatin
Maredia, Hasina , Hand, Jennifer L. , Tollefson, Megha M.

Pediatric Dermatology | September 20, 2023 | Volume: 41 | Issue: 2 | Pages: 296-297

10.1111/pde.15427 | PMID 37726979 Get It

AbstractA 2‐year‐old boy presented with an extensive, asymptomatic, photosensitive eruption refractory to topical steroids and tretinoin; examination and biopsies were consistent with generalized linear porokeratosis involving the face, limbs, and trunk. Treatment with topical cholesterol‐lovastatin was initiated, and it successfully improved early erythematous lesions. Whole exome sequencing that targeted mevalonate pathway genes crucial in cholesterol synthesis later revealed a pathogenic, paternally inherited, porokeratosis‐associated MVD, c.70+5 G>A, mutation. Topical cholesterol‐lovastatin is a safe and effective empiric treatment for porokeratosis when used in the early, erythematous phase, and its success is likely mediated through its role in targeting mevalonate pathway mutations.
Dermatomyositis in Association With SARS‐CoV‐2 Infection or COVID‐19 Vaccine
Diaz‐Menindez, Maximiliano , Sullivan, Megan M. , Majithia, Vikas , Abril, Andy , Butendieck, Ronald R., Ball, Colleen T. , Berianu, Florentina , Majithia, Vikas , Sullivan, Megan M , Wang, Benjamin X.

Arthritis Care & Research | September 20, 2023 | Volume: 76 | Issue: 1 | Pages: 98-104

10.1002/acr.25236 | PMID 37728071 Get It

ObjectiveNew‐onset and relapsed dermatomyositis (DM) has been reported following SARS‐CoV‐2 infection or COVID‐19 vaccination. This study aims to show the characteristics of a DM cohort after COVID‐19 infection and vaccination.MethodsA retrospective review was performed on patients treated for DM between March 1, 2020, and October 31, 2022. Charts were evaluated for the presence of new‐onset DM or relapse of preexisting DM following either SARS‐CoV‐2 infection or COVID‐19 vaccination. Data on symptom onset, timing of vaccination, type of vaccination, and disease characteristics were collected.ResultsNinety‐eight patients treated for DM at our institution in the Division of Rheumatology were included. In total, 12 of 98 patients (12.2%) experienced DM symptoms (either incident or relapse) following either infection or vaccination. Of the 12 patients who developed incident disease or relapse, 7 (58.3%) developed postinfection symptoms, and 8 (66.7%) developed symptoms after vaccination (3 patients had symptoms following both infection and vaccination). The mean onset of symptoms following COVID‐19 infection was 3.2 days (median 0.5 days), and mean onset following COVID‐19 vaccination was 5.75 days (median 3.5 days). Nine of 12 patients (75%) had a positive myositis‐specific antibody, and the remaining 3 (25%) had myositis‐associated antibodies. There was no predominant vaccine associated with the development of postvaccination DM symptoms.ConclusionThis retrospective review revealed a strong temporal relationship between DM symptoms and COVID‐19 infection or vaccination in 12.2% of all patients with DM evaluated in our clinic during the pandemic. Additional studies are required to understand the possible pathophysiology behind this association.